Methods for treating neurodegenerative disease using anti-PD-1 antibodies
First Claim
Patent Images
1. A method of treating or reducing the risk of a neurodegenerative disease in a human, the method comprising administering to said human an anti-PD-1 antibody or antibody fragment that specifically binds to a human PD-1 that is expressed by a PD-1 nucleotide sequence comprising a variation selected from the group consisting of:
- rs7568402;
rs28699177;
rs28542728;
rs118117097;
rs28570544;
rs118027315;
rs191919871;
rs6707556;
rs142909968;
rs36084323;
rs10204225;
rs11568821;
rs2227981; and
rs2227982;
wherein the antibody or antibody fragment that specifically binds to human PD-1 comprises;
(i) a human gamma-1 heavy chain constant region that comprises an amino acid selected from the group consisting of;
an Asp corresponding to position 204 of SEQ ID NO;
42 and a Leu corresponding to position 206 of SEQ ID NO;
42;
or(ii) a human gamma-4 heavy chain constant region that comprises an amino acid selected from the group consisting of;
a Leu corresponding to position 189 of SEQ ID NO;
73 and a Arg corresponding to position 289 of SEQ ID NO;
73; and
wherein the antibody is or antibody fragment comprises the variable domains of an antibody selected from the group consisting of pembrolizumab and nivolumab;
wherein said human comprises;
(iii) an IGHG1*01 human heavy chain constant region gene segment, or the human expresses antibodies comprising human gamma-1 heavy chain constant regions comprising said selected amino acid of clause (i), when the antibody or fragment is according to clause (i);
or(iv) an IGHG4*01 human heavy chain constant region gene segment, or the human expresses antibodies comprising human gamma-4 heavy chain constant regions comprising said selected amino acid of clause (ii), when the antibody or fragment is according to clause (ii); and
wherein said human comprises;
(v) a PD-1 nucleotide sequence comprising said selected variation; and
wherein the neurodegenerative disease is selected from the group consisting of Alzheimer'"'"'s disease, Parkinson'"'"'s disease, and Huntington'"'"'s disease.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention relates to human targets of interest (TOI), anti-TOI ligands, kits compositions and method.
158 Citations
20 Claims
-
1. A method of treating or reducing the risk of a neurodegenerative disease in a human, the method comprising administering to said human an anti-PD-1 antibody or antibody fragment that specifically binds to a human PD-1 that is expressed by a PD-1 nucleotide sequence comprising a variation selected from the group consisting of:
-
rs7568402;
rs28699177;
rs28542728;
rs118117097;
rs28570544;
rs118027315;
rs191919871;
rs6707556;
rs142909968;
rs36084323;
rs10204225;
rs11568821;
rs2227981; and
rs2227982;wherein the antibody or antibody fragment that specifically binds to human PD-1 comprises; (i) a human gamma-1 heavy chain constant region that comprises an amino acid selected from the group consisting of; an Asp corresponding to position 204 of SEQ ID NO;
42 and a Leu corresponding to position 206 of SEQ ID NO;
42;
or(ii) a human gamma-4 heavy chain constant region that comprises an amino acid selected from the group consisting of; a Leu corresponding to position 189 of SEQ ID NO;
73 and a Arg corresponding to position 289 of SEQ ID NO;
73; andwherein the antibody is or antibody fragment comprises the variable domains of an antibody selected from the group consisting of pembrolizumab and nivolumab; wherein said human comprises; (iii) an IGHG1*01 human heavy chain constant region gene segment, or the human expresses antibodies comprising human gamma-1 heavy chain constant regions comprising said selected amino acid of clause (i), when the antibody or fragment is according to clause (i);
or(iv) an IGHG4*01 human heavy chain constant region gene segment, or the human expresses antibodies comprising human gamma-4 heavy chain constant regions comprising said selected amino acid of clause (ii), when the antibody or fragment is according to clause (ii); and wherein said human comprises; (v) a PD-1 nucleotide sequence comprising said selected variation; and wherein the neurodegenerative disease is selected from the group consisting of Alzheimer'"'"'s disease, Parkinson'"'"'s disease, and Huntington'"'"'s disease. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20)
b. at least one oligonucleotide probe comprising a sequence of at least 10 contiguous nucleotides of a nucleotide sequence comprising said selected variation or comprising an antisense sequence of said contiguous nucleotides, wherein said sequence of contiguous nucleotides comprises said selected variation thereby forming a complex when the nucleotide sequence comprising said selected variation is present; and detecting the presence or absence of the complex, wherein detecting the presence of the complex determines that the human comprises a PD-1 nucleotide sequence comprising said selected variation.
-
-
11. The method of claim 9, wherein the assaying comprises nucleic acid amplification and optionally one or more methods selected from sequencing, next generation sequencing, nucleic acid hybridization, and allele-specific amplification and/or wherein the assaying is performed in a multiplex format.
-
12. The method of claim 1, wherein said human is or has been further determined to be substantially resistant to a PD-L1 or PD-1 treatment.
-
13. The method of claim 1, wherein said human is receiving or has received a PD-L1 or PD-1 treatment or has reduced responsiveness to a PD-L1 or PD-1 treatment.
-
14. The method of claim 9, wherein said biological sample comprises serum, blood, faeces, tissue, a cell, urine and/or saliva of said human.
-
15. The method of claim 1, wherein said antibody or antibody fragment that specifically binds to human PD-1 is administered by intravenous or subcutaneous injection and/or is comprised in an injectable preparation.
-
16. The method of claim 1, wherein the antibody or antibody fragment that specifically binds to human PD-1 is a human antibody or antibody fragment.
-
17. The method of claim 1, wherein the antibody is pembrolizumab or an antibody fragment thereof that specifically binds to a human PD-1.
-
18. The method of claim 1, wherein the antibody is nivolumab or an antibody fragment thereof that specifically binds to a human PD-1.
-
19. The method of claim 2, wherein the antibody is pembrolizumab or an antibody fragment thereof that specifically binds to a human PD-1.
-
20. The method of claim 2, wherein the antibody is nivolumab or an antibody fragment thereof that specifically binds to a human PD-1.
Specification